Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study - Concepedia

Concepedia

Publication | Open Access

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study

DOI Full Paper Access

406

Citations

33

References

2020

Year

Lecia V. Sequist, Ji‐Youn Han, Myung‐Ju Ahn, Byoung Chul Cho, Helena A. Yu, Sang-We Kim, James Chih‐Hsin Yang, Jong Seok Lee, Wu‐Chou Su, Dariusz M. Kowalski,

The Lancet Oncology

Abstract

AstraZeneca.

References

	Year	Citations

Page 1